CompletedNCT02260830
How Different Lu AF11167 Tablets Are Absorbed in the Body
About this title
Read the official source — NCT02260830Medication studyAges 18–45United KingdomSchizophrenia
Understand this study
Who was this study for?
This study was for healthy volunteers. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.
- Listed locations
- NottinghamSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateAugust 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 28
- Sponsor
- H. Lundbeck A/S
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United Kingdom
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT02260830
- Official title
Show the full official title
Interventional, Open-label, Part Fixed Sequence, Part-randomised Study Investigating the Pharmacokinetic Properties of up to 6 Prototype Modified Release Tablet Formulations of Lu AF11167 in Healthy Young Subjects
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Nottingham
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is H. Lundbeck A/S.
Did this study involve medication?
Yes. The study involved medication, including Lu AF11167.
Who was this study for?
This study was for healthy volunteers. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.
